Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

BACKGROUND: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; Stribild(®)) is a recommended integrase inhibitor-based regimen in treatment guidelines from the US Department of Health and Human Services and the British HIV Association. The purp...

Descripción completa

Detalles Bibliográficos
Autores principales: Gathe, Joseph, Arribas, Jose R., Van Lunzen, Jan, Garner, Will, Speck, Rebecca M., Bender, Randall, Shreay, Sanatan, Nguyen, Thai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575373/
https://www.ncbi.nlm.nih.gov/pubmed/26286337
http://dx.doi.org/10.1007/s40271-015-0137-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575373/
https://www.ncbi.nlm.nih.gov/pubmed/26286337
http://dx.doi.org/10.1007/s40271-015-0137-9

Ejemplares similares